Deciphera Pharmaceuticals announced a restructuring with the intention of prioritizing clinical development of specific programs and streamlining the Waltham, Mass.-based company’s commercial operations. In addition to cutting one of its programs, Deciphera plans to reduce about 140 positions.

It’s not unusual for biopharma companies to end the year with a restructuring that includes job cuts. Rigel Pharmaceuticals announced a 16 percent reduction of the company’s workforce, most in early research. 

Zymergen announced that the company is letting go about 220 employees after deciding to restructure and discontinue its consumer care and electronics film programs, among others. 

Gemini Therapeutics announced Oct. 5 that the company is reducing employee headcount by 20 percent and ceasing some research and non-clinical programs as part of a corporate restructuring effort to focus on a clinical trial for geographic atrophy.

Less than a month after appointing a new chief executive officer, Ziopharm Oncology  announced a restructure that resulted in more than 50 percent of the company’s workforce being axed.

After receiving a Complete Response Letter (CRL) from the U.S. Food and Drug Administration for the New Drug Application for tenapanor for control of serum phosphorus in adults with chronic kidney disease on dialysis, Waltham, Mass.-based Ardelyx is restructuring to save money.

DBV Technologies unveiled a global restructuring plan that will result in a reduction of more than 200 jobs.

Shares of Endo International were up after announcing positive earnings and a new restructuring plan that is expected to “optimize” the company’s operations through the elimination of several manufacturing sites and the employees who work there.

Three biopharma companies recently shuttered their clinical programs after either their drug compounds failed clinical trials or interim futility analysis suggested they were unlikely to meet their clinical endpoints.

Less than a month after the failure of a Phase III Duchenne muscular dystrophy (DMD) trial, Switzerland-based Santhera Pharmaceuticals announced a corporate restructuring that includes the termination of 50 percent of the company’s workforce.